|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Net revenue | |||||
| Cost of revenues | |||||
| Cost of revenues – amortization of acquired intangibles | |||||
| Gross profit | |||||
| Operating expenses: | |||||
| Research and development | |||||
| Sales and marketing | |||||
| General and administrative | |||||
| Change in fair value of contingent consideration | |||||
| Impairment losses | |||||
| Impairment loss on held for sale assets | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other (expenses) income: | |||||
| Interest expense | |||||
| Loss on marketable equity securities | |||||
| Other income, net | |||||
| Total other income, net | |||||
| Loss from continuing operations | |||||
| Loss before income taxes | |||||
| Loss from discontinued operations (Note 13) | |||||
| Income taxes | |||||
| Net loss | |||||
| Less: dividends and accretion of Series A redeemable convertible preferred stock | |||||
| Net loss per share (Note 2): | |||||
| Net loss from continuing operations - basic | |||||
| Net loss from discontinued operations - basic | |||||
| Net loss from discontinued operations - diluted | |||||
| Net loss attributable to common stockholders - basic | |||||
| Net loss attributable to common stockholders - diluted | |||||
| Net loss from continuing operations per share - basic | |||||
| Net loss from discontinued operations per share - basic | |||||
| Net loss attributable to common stockholders per share - basic | |||||
| Net loss attributable to common stockholders per share - diluted | |||||
| Weighted average shares outstanding - basic | |||||
| Weighted average shares outstanding - diluted | |||||
Loading...